Annual Cash & Cash Equivalents
$3.13 M
-$692.00 K-18.12%
31 March 2024
Summary:
Sonoma Pharmaceuticals annual cash & cash equivalents is currently $3.13 million, with the most recent change of -$692.00 thousand (-18.12%) on 31 March 2024. During the last 3 years, it has fallen by -$1.09 million (-25.88%). SNOA annual cash & cash equivalents is now -83.58% below its all-time high of $19.05 million, reached on 31 March 2007.SNOA Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$4.08 M
+$1.49 M+57.51%
30 September 2024
Summary:
Sonoma Pharmaceuticals quarterly cash and cash equivalents is currently $4.08 million, with the most recent change of +$1.49 million (+57.51%) on 30 September 2024. Over the past year, it has increased by +$1.67 million (+69.49%). SNOA quarterly cash and cash equivalents is now -78.59% below its all-time high of $19.05 million, reached on 31 March 2007.SNOA Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SNOA Cash And Cash Equivalents Performance
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | -18.1% | +69.5% |
3 y3 years | -25.9% | -52.2% |
5 y5 years | -15.2% | +9.4% |
SNOA Cash And Cash Equivalents High & Low
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3 years | -57.7% | at low | -52.2% | +90.8% |
5 y | 5 years | -57.7% | at low | -52.2% | +90.8% |
alltime | all time | -83.6% | +1667.2% | -78.6% | +112.3% |
Sonoma Pharmaceuticals Cash And Cash Equivalents History
Date | Annual | Quarterly |
---|---|---|
Sept 2024 | - | $4.08 M(+57.5%) |
June 2024 | - | $2.59 M(-17.2%) |
Mar 2024 | $3.13 M(-18.1%) | $3.13 M(+30.0%) |
Dec 2023 | - | $2.41 M(+12.6%) |
Sept 2023 | - | $2.14 M(-39.7%) |
June 2023 | - | $3.54 M(-7.2%) |
Mar 2023 | $3.82 M(-48.4%) | $3.82 M(+45.0%) |
Dec 2022 | - | $2.63 M(-21.4%) |
Sept 2022 | - | $3.35 M(-40.0%) |
June 2022 | - | $5.59 M(-24.5%) |
Mar 2022 | $7.40 M(+75.3%) | $7.40 M(-13.3%) |
Dec 2021 | - | $8.53 M(+1.6%) |
Sept 2021 | - | $8.39 M(+198.5%) |
June 2021 | - | $2.81 M(-33.4%) |
Mar 2021 | $4.22 M(+14.3%) | $4.22 M(-23.8%) |
Dec 2020 | - | $5.54 M(+28.3%) |
Sept 2020 | - | $4.32 M(-5.1%) |
June 2020 | - | $4.55 M(+23.3%) |
Mar 2020 | $3.69 M(+0.1%) | $3.69 M(-1.0%) |
Dec 2019 | - | $3.73 M(+15.3%) |
Sept 2019 | - | $3.23 M(-24.6%) |
June 2019 | - | $4.28 M(+16.1%) |
Mar 2019 | $3.69 M(-63.4%) | $3.69 M(-43.2%) |
Dec 2018 | - | $6.50 M(+60.5%) |
Sept 2018 | - | $4.05 M(-47.3%) |
June 2018 | - | $7.68 M(-23.7%) |
Mar 2018 | $10.07 M(-42.4%) | $10.07 M(+16.7%) |
Dec 2017 | - | $8.63 M(-13.6%) |
Sept 2017 | - | $9.98 M(-21.0%) |
June 2017 | - | $12.64 M(-27.6%) |
Mar 2017 | $17.46 M(+133.8%) | $17.46 M(-8.0%) |
Dec 2016 | - | $18.98 M(+483.4%) |
Sept 2016 | - | $3.25 M(-34.5%) |
June 2016 | - | $4.97 M(-33.5%) |
Mar 2016 | $7.47 M(+21.7%) | $7.47 M(+22.2%) |
Dec 2015 | - | $6.11 M(-23.3%) |
Sept 2015 | - | $7.97 M(-8.9%) |
June 2015 | - | $8.75 M(+42.6%) |
Date | Annual | Quarterly |
---|---|---|
Mar 2015 | $6.14 M(+12.0%) | $6.14 M(+173.9%) |
Dec 2014 | - | $2.24 M(-36.9%) |
Sept 2014 | - | $3.55 M(-28.8%) |
June 2014 | - | $4.99 M(-9.0%) |
Mar 2014 | $5.48 M(-30.6%) | $5.48 M(+59.4%) |
Dec 2013 | - | $3.44 M(+7.7%) |
Sept 2013 | - | $3.19 M(-40.7%) |
June 2013 | - | $5.38 M(-31.9%) |
Mar 2013 | $7.90 M(+135.8%) | $7.90 M(+19.7%) |
Dec 2012 | - | $6.60 M(-20.6%) |
Sept 2012 | - | $8.31 M(+88.9%) |
June 2012 | - | $4.40 M(+31.3%) |
Mar 2012 | $3.35 M(-23.3%) | $3.35 M(-32.5%) |
Dec 2011 | - | $4.96 M(+37.0%) |
Sept 2011 | - | $3.62 M(-27.9%) |
June 2011 | - | $5.03 M(+15.0%) |
Mar 2011 | $4.37 M(-30.2%) | $4.37 M(-6.5%) |
Dec 2010 | - | $4.67 M(-12.9%) |
Sept 2010 | - | $5.37 M(-19.5%) |
June 2010 | - | $6.67 M(+6.5%) |
Mar 2010 | $6.26 M(+225.8%) | $6.26 M(+21.3%) |
Dec 2009 | - | $5.16 M(-20.1%) |
Sept 2009 | - | $6.45 M(+214.3%) |
June 2009 | - | $2.05 M(+6.9%) |
Mar 2009 | $1.92 M(-89.8%) | $1.92 M(-20.6%) |
Dec 2008 | - | $2.42 M(-59.5%) |
Sept 2008 | - | $5.97 M(-47.9%) |
June 2008 | - | $11.46 M(-39.1%) |
Mar 2008 | $18.82 M(-1.2%) | $18.82 M(+81.8%) |
Dec 2007 | - | $10.35 M(-30.7%) |
Sept 2007 | - | $14.95 M(+16.3%) |
June 2007 | - | $12.85 M(-32.5%) |
Mar 2007 | $19.05 M(+155.8%) | $19.05 M(+656.0%) |
Dec 2006 | - | $2.52 M(+11.1%) |
Sept 2006 | - | $2.27 M(-69.5%) |
Mar 2006 | $7.45 M(+126.6%) | $7.45 M(+126.6%) |
Mar 2005 | $3.29 M(+1757.1%) | $3.29 M |
Mar 2003 | $177.00 K(-76.8%) | - |
Mar 2002 | $764.00 K | - |
FAQ
- What is Sonoma Pharmaceuticals annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Sonoma Pharmaceuticals?
- What is Sonoma Pharmaceuticals annual cash & cash equivalents year-on-year change?
- What is Sonoma Pharmaceuticals quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Sonoma Pharmaceuticals?
- What is Sonoma Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
What is Sonoma Pharmaceuticals annual cash & cash equivalents?
The current annual cash & cash equivalents of SNOA is $3.13 M
What is the all time high annual cash & cash equivalents for Sonoma Pharmaceuticals?
Sonoma Pharmaceuticals all-time high annual cash & cash equivalents is $19.05 M
What is Sonoma Pharmaceuticals annual cash & cash equivalents year-on-year change?
Over the past year, SNOA annual cash & cash equivalents has changed by -$692.00 K (-18.12%)
What is Sonoma Pharmaceuticals quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of SNOA is $4.08 M
What is the all time high quarterly cash and cash equivalents for Sonoma Pharmaceuticals?
Sonoma Pharmaceuticals all-time high quarterly cash and cash equivalents is $19.05 M
What is Sonoma Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
Over the past year, SNOA quarterly cash and cash equivalents has changed by +$1.67 M (+69.49%)